Clarivate Completes $600M Sale of Life Sciences & Healthcare to Altaris
CLVT is trading near its 52-week low of $1.425 (1.8% above the low).
Summary
Clarivate completed the $600M divestiture of its Life Sciences & Healthcare business to Altaris, receiving $500M cash plus $75M note and $25M deferred consideration. The deal sharpens strategic focus and strengthens the balance sheet.
Key Events · M&A and Partnerships · CLVT
-
Divestiture Completed
On October 6, 2026, Clarivate closed the sale of its Life Sciences & Healthcare segment to Altaris, receiving $500M cash, a $75M unsecured note, and $25M deferred consideration.
-
Balance Sheet Strengthening
Proceeds will be used to reduce debt, improving financial flexibility following the Q2 2026 $268.6M net loss and $221.7M goodwill impairment.
-
Executive Departure
Henry Levy, President of Life Sciences & Healthcare, terminated employment upon closing under a previously disclosed retention agreement.
-
Pro Forma Financials Due
Unaudited pro forma condensed consolidated financials are expected to be filed by October 13, 2026.
Analysis · CLVT · Technology
The sale of Clarivate's Life Sciences & Healthcare segment to Altaris has closed, bringing in $500M in cash, a $75M note, and $25M in deferred consideration. This divestiture sharpens the company's focus on its higher-margin Academia & Government and Intellectual Property segments while providing capital to reduce debt. The completion also triggers the departure of segment President Henry Levy. Pro forma financials are due by October 13, 2026, and Q3 results on November 3, 2026 will update guidance to reflect the divestiture.
How filings like this one have moved
In the 30 days to Oct 6, 2026, 28.9% of the 1573 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLVT was trading at $1.45 on NYSE in the Technology sector, with a market capitalization of approximately $940.3M. The 52-week trading range was $1.43 to $3.91. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.